Estimation of Cardiotoxicity in Breast Cancer Patients Using Presmoothing and Cure Models

UDC.coleccionPublicacións UDCes_ES
UDC.endPage466es_ES
UDC.startPage461es_ES
dc.contributor.authorSaavedra, S.
dc.contributor.authorLópez-Cheda, Ana
dc.contributor.authorJácome, M. A.
dc.date.accessioned2025-02-10T17:28:37Z
dc.date.available2025-02-10T17:28:37Z
dc.date.issued2024
dc.description.abstractBreast cancer is the most common type of cancer for women. Nowadays, the side-effects that some treatments against this type of cancer can be a major problem. One example of this is HER2-positive breast cancer patients. Patients are prescribed trastuzumab, a drug with anti-tumour efficacy, but this treatment can cause various undesirable effects such as heart problems, known as cardiotoxicity. With the aim of improving the quality of life of those affected, the question is clear: what is the likelihood of suffering cardiotoxicity? In this work, this probability is estimated using a new approach to the classic cure models: the presmoothed cure models.es_ES
dc.identifier.urihttp://hdl.handle.net/2183/41135
dc.language.isoenges_ES
dc.relation.urihttps://doi.org/10.17979/spudc.9788497498913.65
dc.rightsAtribución 4.0es_ES
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectHER2-positive breast cancer patientses_ES
dc.subjectDrugses_ES
dc.subjectComplexo Hospitalario Universitario da Coruña (CHUAC)es_ES
dc.subjectCánceres_ES
dc.subjectMortality ratees_ES
dc.titleEstimation of Cardiotoxicity in Breast Cancer Patients Using Presmoothing and Cure Modelses_ES
dc.typeconference outputes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationf9659505-c936-495e-b527-e2dc0b2a34f5
relation.isAuthorOfPublication811e9787-a857-4c18-8295-268b4014b4bc
relation.isAuthorOfPublicatione629ebcc-3475-4638-b4e7-bf3e786f997c
relation.isAuthorOfPublication.latestForDiscoveryf9659505-c936-495e-b527-e2dc0b2a34f5

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
XoveTIC_2024_proceedings_Parte65.pdf
Size:
720.26 KB
Format:
Adobe Portable Document Format
Description: